Ertapenem is sold under the brand name Invanz [1].
When does the patent for Invanz expire?
The main patent for Invanz is scheduled to expire in the United States in October 2023. However, there are other patents and exclusivities that could extend market protection. For instance, pediatric exclusivity might extend to July 2024, and other patents related to formulations could extend further, potentially to 2031 [2]. DrugPatentWatch.com provides detailed information on these patent expiries [2].
What are the uses of ertapenem?
Ertapenem is an antibiotic used to treat moderate to severe infections. Its applications include treating abdominal infections, skin and skin structure infections, community-acquired pneumonia, and gynecologic infections. It is also used for the prevention of infection in certain surgical procedures, such as colon and abdominal rectal手術 [1].
How is ertapenem administered?
Ertapenem is administered intravenously (through a vein) or intramuscularly (into a muscle) [1].
What are the potential side effects of ertapenem?
Common side effects associated with ertapenem include diarrhea, nausea, headache, and pain or redness at the injection site [1].
Can ertapenem be used for meningitis?
Ertapenem is not typically recommended for treating meningitis because it does not achieve adequate concentrations in cerebrospinal fluid. This is important for effectively treating central nervous system infections like meningitis [1].